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Formyl-peptide receptor type 2 (FPR2), also called ALX (the lipoxin
A4 receptor), conveys the proresolving properties of lipoxin A4
and annexin A1 (AnxA1) and the proinﬂammatory signals elicited
by serum amyloid protein A and cathelicidins, among others. We
tested here the hypothesis that ALX might exist as homo- or het-
erodimer with FPR1 or FPR3 (the two other family members) and
operate in a ligand-biased fashion. Coimmunoprecipitation and
bioluminescence resonance energy transfer assays with trans-
fected HEK293 cells revealed constitutive dimerization of the
receptors; signiﬁcantly, AnxA1, but not serum amyloid protein A,
could activate ALX homodimers. A p38/MAPK-activated protein
kinase/heat shock protein 27 signaling signature was unveiled af-
ter AnxA1 application, leading to generation of IL-10, as measured
in vitro (in primary monocytes) and in vivo (after i.p. injection in
the mouse). The latter response was absent in mice lacking the ALX
ortholog. Using a similar approach, ALX/FPR1 heterodimerization
evoked using the panagonist peptide Ac2-26, identiﬁed a JNK-medi-
ated proapoptotic path that was conﬁrmed in primary neutrophils.
These ﬁndings provide a molecular mechanism that accounts for the
dual nature of ALX and indicate that agonist binding and dimeriza-
tion state contribute to the conformational landscape of FPRs.
inﬂammation | leukocyte | resolution signaling
G-protein–coupled receptors (GPCRs) constitute a largefamily of cell surface receptors that share structural char-
acteristics and perform pivotal biological functions, transducing
signals from hormones, autacoids, and chemokines. The human
GPCR termed “ALX/FPR2” (formyl peptide receptor type 2 or
lipoxin A4 receptor, hereafter referred to as “ALX”) is a unique
GPCR, shown to convey signals induced by proteins, peptides,
and lipid ligands (1). ALX belongs to a small family of receptors
that is also activated by formylated peptides, short amino acid
sequences with an N-terminal formyl group released by patho-
genic and commensal bacteria, as well as by mitochondria upon
cell damage. There are three human FPRs and they are termed
FPR1, ALX, and FPR3 (2). In view of their different nature and
potential engagement with a large number endogenous and ex-
ogenous ligands, elucidation of FPR functions may reveal im-
portant biological pathways.
ALX is an unconventional receptor for the diversity of its
agonists and because it can convey contrasting biological signals.
The proresolving and anti-inﬂammatory properties of the pro-
tein annexin A1 (AnxA1) and the lipid lipoxin A4 (LXA4), which
include neutrophil apoptosis and macrophage efferocytosis, are
mediated by this receptor, as shown using pharmacological
approaches (1, 3) and more recently with knockout mouse
models (4). At the same time, the proinﬂammatory responses
elicited by the cathelicidin-associated antimicrobial peptide LL-37
and serum amyloid protein A (SAA) are also mediated by ALX,
which modulates leukocyte activation, recruitment to the site
of inﬂammation, and lifespan (5–7). Moreover, LXA4 and
AnxA1 engage ALX to favor a macrophage M2 phenotype,
whereas LL-37 and SAA used the same receptor to induce an M1
phenotype (8). In a similar vein using human neutrophils, nano-
molar concentrations of LXA4 counteracted LL-37–mediated re-
lease of leukotriene B4, both actions being conveyed by ALX (9).
Using resonance energy transfer (RET) techniques to investigate
GPCR interactions, a number of studies reported agonist stimu-
lation to initiate dimerization between certain GPCRs, which may
otherwise exist as monomeric structures (10) or that agonists
enhance the interaction between preformed dimers (11). Agonist-
induced changes in RET signal could be attributed to confor-
mational changes occurring within the receptor in response to
agonist binding (12). Finally, activation of downstream signaling
pathways may also inﬂuence conformational changes within the
receptors (13, 14). We tested here whether the ability of ALX to
transduce the bioactions elicited by distinct agonists is modulated
by conformational changes.
Results
Homo-/Heterodimerization of FPR1 with ALX and FPR3 Is Enhanced by
a Panagonist Peptide. HEK293 cells were used for a trans-
fection-based approach to investigate the potential homo-/
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heterodimerization between FPRs and chosen because they do
not express any of the three receptors (Fig. S1A). Initial analyses
determined that the epitope-tagged constructs were properly
expressed on the cell surface 24 h posttransfection (Fig. S1 B and
C). Colocalization between the FPR1 and ALX at the cell surface
was observed (Fig. 1A). To monitor physical interaction between
the receptors, HEK293 cells were transfected with FPR1 ×
3Flag construct along with either FPR1 × 3HA, ALX × 3HA
or FPR3 × 3HA constructs for immunoprecipitation (IP) with
an anti-HA antibody. Using this protocol, we observed that
FPR1 can constitutively homodimerize and heterodimerize
with ALX and FPR3 (Fig. S1D). This effect was not modiﬁed
by addition of the panagonist peptide Ac2-26 [annexin A1 N
terminal peptide Ac2–26 (acetyl-AMVSEFLKQAWIENEE-
QEYVVQTVK)] (15). Next, we used the bioluminescence
RET (BRET) technique to explore receptor interaction in
living cells.
HEK293 cells transfected with FPR1-enhanced YFP (EYFP)
and FPR1-Renilla luciferase (Rluc), FPR1-EYFP and ALX-
Rluc, or FPR1-Rluc and FPR3-EYFP constructs showed an in-
teraction between these receptors as determined by detection
of BRET signal in absence of agonist application. Addition of
peptide Ac2-26 (10−5 M), although not affecting the BRET
signal between FPR1 homodimers or FPR1-FPR3 heterodimers,
produced a signiﬁcant enhancing effect on FPR1-ALX hetero-
dimer signal (Fig. 1B). To rule out the possibility of nonspeciﬁc
interactions, we investigated whether the FPR1 and ALX recep-
tors could form heterodimers with another class A GPCR, namely,
the angiotensin 1 receptor. These receptors did not interact, nor
was a signal obtained upon addition of the respective agonists
Ac2-26 or angiotensin II, as determined by BRET and co-IP
techniques (Fig. S2).
We then focused on the interaction between the FPR1 and
ALX. The anti-inﬂammatory agonists AnxA1 (10−8 M), peptide
Ac2-26 (10−5 M), and LXA4 (10
−7 M), together with the small
molecule compound 43 (Cpd43; 10−6 M), produced a signiﬁcant
enhancement in BRET signal (Fig. 1C). Complete physical val-
idation of the LXA4 agonist was carried out using liquid chro-
matography-tandem mass spectrometry (LC-MS-MS) and UV,
with spectra and proﬁles matching those reported earlier (Fig.
S3) (16). The BRET response was not obtained with SAA
(10−7 M) or the selective FPR1 or ALX antagonists (cyclo-
sporin H and WRW4, respectively) (Fig. 1C). In line with
FPR1 dimerization (Fig. S1D), addition of these ligands did
not enhance the co-IP between FPR1 and ALX (Fig. 1D). The
central role seemingly played by ALX in the observed agonist-
speciﬁc conformational changes prompted us to test homo-
dimerization responses.
Contrasting Effect of AnxA1 and SAA on ALX Homodimerization.
Homodimerization of ALX was investigated with ALX × 3Flag
and ALX × 3HA constructs, followed by IP with anti-HA and
immunoblotting with anti-Flag antibody. Addition of AnxA1
(10−8 M), Ac2-26 (10−5 M), or SAA (10−7 M) did not inﬂuence
receptor dimerization, and a band corresponding to the correct
molecular weight for an ALX dimer was observed (Fig. 2A).
ALX dimerization was investigated in living cells following
transfection with ALX-Rluc and ALX-EYFP constructs. At 24 h
posttransfection, cells were stimulated with AnxA1 (10−8 M),
Ac2-26 (10−5 M), or SAA (10−7 M) for 10 min. As was seen with
the FPR1-ALX heterodimer (Fig. 1), peptide Ac2-26 produced
an enhanced BRET signal (Fig. 2B). ALX anti-inﬂammatory and
proinﬂammatory ligands displayed opposite effects: AnxA1 en-
hanced, whereas SAA decreased, the BRET signal (Fig. 2B). At
10−9 M, AnxA1 elicited a similar BRET signal (2.2 ± 0.4-fold
increase over basal; n = 3). Representative real-time BRET
analysis plots display single-order kinetics in response to Ac2-26
and AnxA1, but not SAA (Fig. 2C). Tested at 10−7 M, LXA4
enhanced the BRET signal between ALX homodimers (Fig.
S4A). Of interest, this bioactive lipid did not interfere with the
BRET signal provoked by AnxA1. SAA, over a wide range of
concentrations (up to 3 × 10−6 M), failed to incite a BRET re-
sponse (Fig. S4B); however, it attenuated the enhancement in
BRET signal provoked by AnxA1 (Fig. S4A). Collectively, these
results shed some light into the conﬂicting behavior imposed on
ALX by functionally different agonists, indicating, presumably,
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Fig. 1. Expression and dynamics of FPR1 in transfected HEK293 cells. (A)
HEK293 cells were transfected with HA-FPR1 (red) and Flag-ALX (green); re-
ceptor colocalization shown in the merged image (yellow). Data represen-
tative of three analyses conducted with different cell preparations. (B) FPR1
homodimerization and heterodimerization with ALX and FPR3 using BRET.
HEK293 cells transfected with FPR1-EYFP and FPR1-Rluc, FPR1-EYFP and ALX-
Rluc, or FPR1-Rluc and FPR3-EYFP constructs were stimulated with Ac2-26
(10−5 M) for 10 min. Data (mean ± SEM of three experiments) are calculated
against unstimulated ALX/FPR1 values. **P < 0.01, ***P < 0.001 vs. control
(FPR1-EYFP/FPR1-RLuc cells). (C) FPR1/ALX heterodimerization. FPR1-EYFP and
ALX-Rluc were coexpressed in HEK293 cells and, after 24 h, incubated with
AnxA1 (10−8 M), SAA (10−7 M), compound 43 (Cpd43; 10−6 M), Ac2-26
(10−5 M), LXA4 (10
−7 M), cyclosporin H (CycH; 10−5 M), or WRW4 (10−5 M) for
10 min. As positive controls for the assays, cells were transfected with
β-arrestin–Rluc and angiotensin II receptor type 1 (AT1R)-EYFP constructs and
stimulated with angiotensin II (AngII; 10−6 M) for 10 min. Data are mean ±
SEM of three experiments in triplicate. *P < 0.05, **P < 0.01 vs. control (FPR1-
EYFP and ALX-Rluc cells). ***P < 0.001 for AngII-treated cells vs. respective
control. (D) Heterodimerization between FPR1 and ALX. FPR1 × 3HA and
ALX × 3Flag-transfected HEK293 cells were stimulated with the indicated
agonists as in B. Immunoprecipitation of FPR1 × 3HA with HA agarose beads
coprecipitated ALX × 3Flag as determined by immunoblotting with anti-Flag
antibody. Blots are representative of three independent experiments.



















Deﬁnition of a Speciﬁc Signaling Pathway Activated by the AnxA1/
ALX Interaction. Initially we established that ALX functioned nor-
mally in that Cpd43, SAA, and AnxA1 provoked dephosphorylation
of moesin in HEK293 cells transfected with ALX (Fig. S5). We
then attempted to elucidate unique signaling pathways using a hu-
man proteome proﬁler MAPK assay (SI Materials and Methods).
Upon addition of AnxA1 (10−8 M) or SAA (10−7 M) onto HEK293
cells transfected with ALX, differences in a number of signaling
molecules emerged (Figs. S6 and S7). Close analysis indicated
potential engagement by AnxA1 of a unique pathway, onto
which we focused the next series of experiments.
Addition of AnxA1 to ALX-HEK293 cells provoked down-
stream phosphorylation of p38, MAPK-activated protein kinase
(MAPKAPK), and the small heat-shock protein Hsp27 (Fig.
S6B) as assessed by Western blotting. Importantly, these data
were conﬁrmed in nontransfected human monocytic U937 cells
(Fig. 3A), which constitutively express ALX (Fig. S1A), and
human primary monocytes (Fig. 3A), which also express ALX
(2). In Fig. 3A (bar graph) we report the cumulative data of four
experiments conducted with primary monocytes, showing that
AnxA1, but not SAA, can induce phospho-Hsp27. AnxA1
phosphorylated Hsp27 in a concentration-dependent fashion,
with higher efﬁcacy at 10−7 M (Fig. S8A). Like SAA, the
proinﬂammatory ALX agonist LL-37 was unable to phosphor-
ylate Hsp27 at any concentrations tested (Fig. S8 B and C).
Finally, we established that phosphorylation of MAPKAPK2
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Fig. 2. Agonist-induced ALX homodimerization. (A) Homodimerization of
ALX as demonstrated using co-IP. HEK293 cells were transfected with either
ALX × 3Flag, ALX × 3HA, or both ALX × 3Flag and ALX × 3HA constructs.
Twenty-four hours later, cells were stimulated with AnxA1 (10−8 M), SAA
(10−7 M), or Ac2-26 (10−5 M) for 10 min. Immunoprecipitation of ALX × 3HA
using anti-HA agarose beads coprecipitated ALX × 3Flag as determined by
immunoblotting with anti-Flag antibody. Blots are representative of three
experiments. (B) Homodimerization of ALX using BRET. HEK293 cells, trans-
fected with ALX-Rluc and ALX-EYFP, were stimulated with the indicated
agonists as in A. Data (mean ± SEM of three experiments) calculated against
basal ALX/ALX values. *P < 0.05, ***P < 0.001 vs. vehicle-treated cells (white
bar). (C) Examples of real-time BRET analysis between ALX-Rluc and ALX-EYFP
expressing HEK293 cells upon application of vehicle (Ctrl), AnxA1 (10−8 M),
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Fig. 3. AnxA1/ALX proresolving signaling signature leads to IL-10 release. (A)
U937 cells (1 × 106) or human primary monocytes (5 × 105) were treated for
10 min with vehicle (Ctrl), AnxA1 (10−8 M) or SAA (10−7 M) and lysates subjected
to Western blotting against phosphorylated and unphosphorylated p38, MAP-
KAPK1, MAPKAPK2, and Hsp27 (representative of three experiments). The cu-
mulative data for Hsp27 are shown in bar graph (n = 3 distinct preparations). (B)
Schema of the p38/MAPKAPK/Hsp27/IL-10 pathway. Human monocytes (1 × 106)
were treated with AnxA1 (10−8 M) for 6 h, with or without pretreatment with
the p38 inhibitor SB203580 (10−7 M, 10 min). Data are mean ± SEM, three
donors assayed in duplicate. **P < 0.01 vs. Ctrl, +++P < 0.001 vs. AnxA1 alone. (C)
AnxA1 (1 μg) or saline (200 μL) were injected i.p. into wild-type or Alx-Fpr2/3
knockout (KO) mice and peritoneal lavages were harvested 6 h later. Data are
mean ± SEM of six mice per group. *P < 0.05 vs. respective wild type. (D) Mice
were treated with 10 mg/kg i.p. LPS and IL-10 levels were measured at the 24-h
time point. (Inset) Endogenous AnxA1 levels in lavage ﬂuids. Data are mean ±
SEM of six mice per group. *P < 0.05 vs. wild type.
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[the kinase upstream of Hsp27 (17, 18) and not present in the
proteome proﬁler] was occurring in human primary monocytes
(Fig. 3A). Collectively, these results indicate that the p38/
MAPKAPK/Hsp27 pathway is a genuine response evoked by
AnxA1, and not SAA, upon activation of ALX.
It was important to corroborate these results in a functional
manner. In monocytes, the p38/MAPKAPK/Hsp27 pathway is
associated with IL-10 generation (Fig. 3B, schema). Stimulation
of isolated monocytes with AnxA1 (10−8 M; 6 h) induced a sig-
niﬁcant release of IL-10 that was abolished by pretreatment of
cells with the p38 inhibitor SB203580 (Fig. 3B). Importantly, this
effect could be replicated in vivo, where i.p. injection of an anti-
inﬂammatory dose of the protein (1-μg equivalent to 27 pmol)
elicited a threefold increase in IL-10 (Fig. 3C). The effect was
absent in Alx-Fpr2/3 KO mice. Then we established the relevance
of this pathway in more complex settings. By 24 h post-LPS,
a marked accumulation of IL-10 had occurred in wild-type but
not Alx-Fpr2/3 KO mice (Fig. 3D). This was not due to differ-
ences in the release of endogenous AnxA1 (similar between
genotypes; Fig. 3D, Inset).
Characterization of FPR1 and ALX Heterodimerization. Finally, we
used a proteome proﬁler to investigate the effect of the pan-
agonist Ac2-26 on HEK293 cells transfected with FPR1, ALX, or
cotransfected with both receptors. A clear difference in signaling
transfected HEK293 cells expressing either FPR1 or ALX, or
cells coexpressing FPR1 and ALX, was detected (Fig. 4A and
Fig. S9). Analysis of the single transfections indicated that the
ALX response was stronger than that observed with FPR1;
however, the most pronounced activation was observed upon
coexpression of both FPR1 and ALX, which showed a selective
activation of the JNK pathway (Fig. 4A, Lower). Proteome data
were conﬁrmed by Western blotting analyses for phospho-ERK
and phospho-JNK in HEK293 cells (Fig. 4B, Top andMiddle) as
well as in primary neutrophils (shown only for phospho-JNK;
Fig. 4B, Bottom).
The JNK pathway has been linked to cell apoptosis (19), a
process AnxA1 promotes in human neutrophils (20). Of note,
this leukocyte type expresses FPR1 and ALX, but not FPR3 (2),
making it ideal to explore heterodimerization in primary cells.
We conducted functional experiments using protocols validated
for LXA4: this ALX agonist abolishes the delay in apoptosis of
SAA-treated neutrophils (7). In line with these studies, addition
of SAA augmented neutrophil lifespan with a signiﬁcant effect at
>6 h (Fig. 5A). Peptide Ac2-26 counteracted this survival signal
and was effective in augmenting the degree of both early and late
apoptosis. Addition of the JNK inhibitor SP600125 abolished
the effect of peptide Ac2-26 (Fig. 5B). We substantiated these
results at the molecular level by monitoring caspase-3 activation.
Addition of peptide Ac2-26 to SAA-treated neutrophils resulted
in caspase-3 cleavage (an effect not visible with SAA alone) and
this was prevented by the JNK inhibitor SP600125 (Fig. 5C).
Discussion
The human FPR termed ALX can elicit opposing responses such
as cell survival vs. death, cell activation vs. inhibition, and in vivo
pro- and anti-inﬂammatory effects. Here we investigated whether
ALX could dimerize and if this conformational event could ac-
count for these biological functions. Using transfected systems, we
found a signiﬁcant change in the BRET signal detected between
the FPR1/ALX heterodimer and ALX/ALX homodimer in re-
sponse to proresolving ALX agonists.
Compared with FPR1 and FPR3 in these experiments, ALX
displayed higher propensity to elicit a BRET signal in response
to agonist stimulation. This feature was shared by distinct pro-
resolving and anti-inﬂammatory agonists, but not by the proin-
ﬂammatory agonist SAA. Thus, it is plausible that agonist-biased
ALX dimerization can distinguish between agonists endowed
with distinct, somewhat opposing biological properties. Because
addition of ALX antagonists, which bind but do not activate the
receptor, did not result in a signiﬁcant change in BRET signal, we
propose that the conformational change of ALX produced by
AnxA1, Ac2-26, LXA4, and Cpd43 was not merely due to ligand–
receptor interaction. These conclusions are substantiated by anal-
ogous observations reported for the β2-adrenergic receptor (21).
Our molecular analyses conﬁrmed that ALX homo- and het-
erodimerization yielded speciﬁc signaling proﬁles. The canonical
Gi-linked GPCR signaling was conﬁrmed by detection of ERK
phosphorylation and moesin dephosphorylation, both well-
characterized readouts of downstream ALX activation (22), but
noteworthy connections were also unveiled. Qualitative results ob-
tained with the proﬁler were supported byWestern blotting analysis,
using the strategy of rapidly translating data obtained with
transfected cells to primary leukocytes. In this manner, we
could deﬁne a “speciﬁc” ALX/ALX dimer signature activated by
AnxA1, but not by SAA or LL-37, which is the p38/MAPKAPK/
Hsp27/IL-10 pathway. Hsp27 is a chaperone protein (for re-
view, ref. 23) endowed with immunomodulatory and anti-
inﬂammatory actions, including the release of IL-10 (24).
It is noteworthy that, whereas LXA4 did not affect the ALX
conformational change promoted by AnxA1, SAA did reduce
this response, thus providing a molecular explanation for the
antagonistic properties of SAA and AnxA1 (25).
AnxA1 addition to cells in vitro augmented IL-10 production in
a p38-mediated fashion. In vivo injections of anti-inﬂammatory
doses of AnxA1 (26) led to IL-10 production in an ALX-
dependent manner, as demonstrated using a mouse colony deﬁcient
in the ortholog for the human receptor (4). Some evidence for
a link between AnxA1 and IL-10 has been advanced in the lit-
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Fig. 4. Identiﬁcation of an ALX/FPR1 signaling signature. (A) Proteome proﬁler
array on HEK293 cells transfected with FPR1, ALX, or both FPR1 and ALX, before
10-min stimulation with Ac2-26 (10−5 M). Control cells were left unstimulated.
(B) Western blotting analysis on HEK293 cells (1 × 106) transfected with human
FPR1, ALX, or FPR1 + ALX to assess the phosphorylation status of ERK and JNK
(Top andMiddle). Jnk phosphorylation in neutrophils stimulated with Ac-26 for
10 min (Bottom). Blots are representative of three individual experiments.



















Our data provide molecular support to this pathway, linking the
protein AnxA1—a master regulator of resolution (29)—and the
cytokine IL-10 to ALX homodimerization. The experiments con-
ducted with LPS indicated that activation of endogenous ALX may
be pivotal for the generation of IL-10, a hypothesis that needs to be
extended to more complex disease models.
We concluded the study by applying the same experimental
approach to deﬁne the signaling signature of the FPR1/ALX
heterodimer. These chimeric analyses indicated that ALX is
more active than FPR1 for phosphosignaling with transfected
cells, and that cotransfection followed by agonist application
elicited a strong JNK response, absent in cells transfected with
just a single receptor. In this set of experiments, we focused on
potential candidates for the apoptosis pathway: AnxA1 and its
peptide Ac2-26, which derives from the N-terminal region of the
protein and may be generated in vivo in inﬂammatory exudates,
promote neutrophil apoptosis in vitro (20) and in vivo (30).
Relevantly, FPR1 and ALX, but not FPR3, are expressed on
human and mouse neutrophils (2); hence, these cells could be
used in the absence of the potential confounding presence of
FPR3. The results obtained with the transfected HEK293 cell
model were therefore validated with primary neutrophils.
Filép and coworkers have described the ability of LXA4 to
override the effects of SAA, a prosurvival factor for human neu-
trophils (7). Fine tuning of neutrophil lifespan is fundamental for
an appropriate inﬂammatory reaction, avoiding the risk for chro-
nicity (31, 32). The ability of peptide Ac2-26 to affect neutrophil
lifespan was abrogated in the presence of JNK inhibition, providing
a functional link to the post-ALX/FPR1 dimerization signaling
events. Supporting these unique data are the association of JNK
in both extrinsic and intrinsic apoptotic pathways (19).
The signaling signature afforded by the ALX/ALX and ALX/
FPR1 dimerization can be exploited to infer speciﬁc engagement
of ALX by proresolving ligands in diseased cells and tissues,
using the p38/MAPKAPK/Hsp27/IL-10 and JNK/caspase-3
pathways as readouts. For instance, we now have the tools to
establish whether ALX/ALX formation failed, or was not fa-
vored, in cells of patients suffering from a given vascular pa-
thology, perhaps explaining the ineffective up-regulation of
protective ligands such as AnxA1 or LXA4 (33). These ﬁndings
are of wide impact because ALX is emerging as an important
regulatory receptor in several distinct human pathologies, rang-
ing from rheumatoid synovitis (34) to human colitis tissue (35),
from ischemic damage (36) to asthma (37). A detailed un-
derstanding of the importance of dimerization evoked by pro-
resolving agonists AnxA1 and LXA4 to ALX biology will clarify
the impact of this receptor on the therapeutic control of path-
ogenic states. For instance, this conformational alteration of
ALX may be relevant for the proresolving properties of resolvin
D1 as described in models of colitis (38). Finally, our unique data
can guide the development of synthetic ALX agonists, including
stable LXA4 analogs (39), peptide mimetics (40), or small mol-
ecules (41), with the ultimate goal of developing innovative
therapeutics to moderate overexuberant inﬂammatory responses.
Materials and Methods
SI Materials and Methods provides an extended version of the experimental
procedures and details of reagents.
Plasmid Constructions, Cell Culture, and Transfections. FPR1-Rluc, ALX-Rluc,
and FPR3- Rluc were generated by subcloning human FPR1, ALX, and FPR3
into the codon humanized Renilla luciferase vectors pRLuc N1 and pRLuc C3.
FPR1 and ALX were cloned into pEYFP-N1 to produce FPR1-EYFP and ALX-
EYFP. FPR1 and ALX were cloned into p3 × Flag–CMV-14 to produce FPR1 ×
3Flag and ALX × 3Flag. FPR1 × 3HA, ALX × 3HA and FPR3 × 3HA were
purchased from Missouri S&T cDNA Resource Center (www.cDNA.org).
HEK293A cells were transfected with Lipofectamine.
Reverse Transcriptase PCR. Total RNA was extracted from HEK293 cells and U937
cells, and cDNA was synthesized for PCR analysis using ALX-speciﬁc primer pairs.
Fluorescence-Associated Cell Sorting and Confocal Microscopy Analyses.
HEK293 cells were transfected with ×3HA-tagged FPRs and stained with
anti-HA antibodies prior to ﬂow cytometry analysis. For colocalization, cells
were cotransfected with HA-tagged FPR1 and FLAG-tagged ALX and, 24 h
later, incubated with anti-FLAG M1 and anti-HA antibody (Sigma). Cells
were ﬁxed with formaldehyde, permeabilized, and stained with secondary
antibody. Coverslips were mounted and visualized using a Zeiss LSM con-
focal microscope (Carl Zeiss).
BRET Assay in Living Cells. HEK293 cells were transfected and 24 h later
transferred into 96-well black Optiplates (Perkin-Elmer). For end-point assays,
cells were stimulated with ligands for 10 min. Coelenterazine-h (Invitrogen)
was added to a ﬁnal concentration of 5 μM and readings were collected
(Polarstar Omega plate reader). For real-time experiments, coelenterazine-h
(5 μM) was added before ligand injection. Cells were kept at 37 °C throughout.
The BRET ratio is deﬁned as emission at 530 nm (light emitted by EYFP)/
emission at 485 (light emitted by Rluc) (13).
Proteome Proﬁler Arrays. FPR1, ALX, or FPR1 + ALX transfected HEK293 cells
were stimulated with AnxA1 (10−8 M), SAA (10−7 M), or Ac2-26 (10−5 M) with
an incubation time of 10 min, using resting cells as control. Protein quanti-
ﬁcation was performed on lysates using the human phospho-MAPK array kit
(R&D Systems).
Isolation of Human Primary Neutrophils and Monocytes. Peripheral blood from
healthy donors was collected in 3.2% (wt/vol) sodium citrate solution (1:10).
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Fig. 5. Peptide Ac2-26 rescues the antiapoptotic effect of SAA. (A and B)
Human neutrophils (1 × 106) were incubated with SAA (10 μg/mL) alone or
with Ac2-26 (10−5 M), before assessment of early (6–12 h) and late (24 h)
apoptosis by ﬂow cytometry (AnxAV- FITC/PI double staining). Experiments
were run in the absence (A) or presence (B) of the JNK inhibitor SP600125
(2 × 10−6 M) added to cells 30 min before. Data are mean ± SEM, n = three
independent donors. *P < 0.05 one-way ANOVA (Ac2-26 vs. 0 concentra-
tion); #P < 0.05 two-way ANOVA (vehicle vs. SAA). (C) Western blotting for
caspase-3 cleavage in human neutrophils treated with SAA alone or to-
gether with Ac2-26 (10−5 M) for 24 h in the presence or absence of SP600125
(2 × 10−6 M). Blot representative of three experiments.
18236 | www.pnas.org/cgi/doi/10.1073/pnas.1308253110 Cooray et al.
1077 gradient. Human primary monocytes were separated using the Ros-
setteSep cell isolation kit (Stem Cell Technologies).
Western Blotting and Coimmunoprecipitations. For dimerization studies, HEK293
cells were transfected with FPR1 × 3Flag, ALX × 3HA and/or FPR1 × 3HA, ALX ×
3HA or FPR3 × 3HA constructs and, 24 h later, stimulated for 10 min with the
agonists. For co-IPs, lysates were incubated with antihemagglutinin (HA)
agarose beads and incubated at room temperature for another 2 h. SDS
loading buffer was added to the samples and subjected to Western blotting
using anti-Flag antibody M2 (1:1,000). Secondary antibody IRDye 800CW goat
anti-mouse IgG was used at a 1:10,000 dilution and imaged using the LI-COR
Odyssey Infrared Image system.
IL-10 Production. Isolated human monocytes (1 × 106) were incubated with
AnxA1 (10−8 M) in the presence or absence of the p38 inhibitor SB203580
(10−7 M; Sigma Aldrich). At 6 h, cell-free supernatants were harvested and
used to quantify human IL-10 levels by ELISA.
Neutrophil Apoptosis. Freshly prepared neutrophils were treated with SAA
(10 μg/mL) in the presence or absence of the JNK inhibitor SP600125 (20 μM)
after a 30-min preincubation with Ac2-26 (0–10−5 M). Cells were then in-
cubated for a further 6–24 h. The apoptosis detection kit from BD Phar-
mingen was used.
Animal Experiments. Male C57BL/6 and Alx-Fpr2/3 KO (4) mice were treated
i.p. with AnxA1 (1 μg; 6 h). In other experiments, mice were injected with
10 mg/kg i.p. of Escherichia coli LPS (serotype 0111:B4). Peritoneal lavages
were used for murine IL-10 and AnxA1 measurements by ELISA.
Statistical Analysis. Statistical analysis was performed using one-way ANOVA
or, in the case of apoptosis in primary cells, two-way ANOVA, taking a P value
less than 0.05 as signiﬁcant.
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SI Materials and Methods
Drugs, Reagents, and Antibodies.Agonists at the lipoxin A4 (LXA4)
receptor termed ALX (also called formyl peptide receptor type 2
or FPR2) used were annexin A1 (a kind gift from Chris Reute-
lingsperger, Maastricht University, Maastricht, The Netherlands)
and LXA4 (EMD Chemicals). Complete physical validation of
lipoxin A4 was obtained with liquid chromatography-tandem
mass spectrometry (LC-MS-MS) and UV matching those re-
ported earlier (1, 2). Fig. S3 reports the MS-MS spectrum and
diagnostic ions conﬁrming the correct structure, the UV-conju-
gated tetraene chromatophore and chromatographic behavior,
three key points for the matching of the material used in the
present experiments. The concentration was determined by UV
spectrometry using absorption at 301 nm (in methanol) and an
extinction coefﬁcient of 40,000. Peptide Ac-AMVSEFLKQAW-
FIENEEQEYVQTVK (Ac2-26) was from Tocris, SAA from
Peprotech, whereas compound 43 (Cpd43; a nitrosylated
pyrazolone derivative with agonistic activity at ALX receptor) was
a generous gift from Amgen (Thousand Oaks, CA). The ALX-
speciﬁc antagonist WRW4 (EMD Chemicals) and the FPR1-spe-
ciﬁc antagonist cyclosporin H were purchased from Biomol. An-
giotensin II was purchased from Sigma-Aldrich.
The p38 inhibitor SB203580 and the JNK inhibitor SP600125
were purchased from Cell Signaling Technologies. Anti-Flag M2,
anti-Flag M1, and anti-HA7 antibodies were purchased from
Sigma-Aldrich; anti-HA11 was purchased from Covance (sup-
plied by Cambridge Bioscience); and Alexa secondary antibodies
(488 and 594) were purchased from Life Technologies. Rabbit
anti-GAPDH was purchased from Santa Cruz Biotechnology,
and Hsp27 mouse mAb, rabbit phospho-heat shock protein-27
(Hsp27), rabbit MAPK-activating protein kinase (MAPKAPK)-2,
phosphoMAPKAPK-2,MAPKAPK1, phosphoMAPKAPK1, p38,
phospho-p38, JNK, phospho-JNK, caspase 3, ERK, and phospho-
ERK antibodies were purchased from Cell Signaling Technology.
Moesin and phospho-Moesin antibodies were purchased from
Abcam. Anti-Flag agarose beads and anti-HA agarose beads were
purchased from Sigma-Aldrich.
Plasmid Constructions, Cell Culture, and Transfections. FPR1-Renilla
luciferase (Rluc), ALX-Rluc, and FPR3-Rluc were generated by
subcloning human FPR1, ALX, and FPR3 into the codon hu-
manized Renilla luciferase vectors pRLuc-N1 and pRLuc-C3
(Perkin-Elmer). FPR1-enhanced yellow ﬂuorescent protein (EYFP)
and ALX-EYFP were generated by cloning FPR1 and ALX into
the expression vectors pEYFP-N1 and -C1 (Clontech). AT1R-
EYFP was generated by subcloning angiotensin II receptor type 1
(AT1R) into pEYFP-N1. β-arrestin–Rluc was generated by
cloning β-arrestin2 into pEYFP-N1 and replacing EYFP with
Rluc (3). FPR1 × 3Flag and ALX × 3Flag constructs were gen-
erated by subcloning human FPR1 and ALX into the p3 × Flag–
CMV-14 vector (Sigma-Aldrich). The FPR1 × 3HA, ALX ×
3HA, and FPR3 × 3HA constructs were obtained from Missouri
S&T cDNA Resource Center (www.cDNA.org). HEK293A cells
were maintained in DMEM containing 10% FCS and 1% peni-
cillin/streptomycin. Cells were transfected with Lipofectamine
2000 (Invitrogen). The U937 monocyte cell line was maintained
in RPMI 1640 supplemented with 10% FCS, 1% l-glutamine,
1% nonessential amino acids, and 1% penicillin/streptomycin.
Cells were kept at 37 °C with 5% CO2.
Reverse Transcriptase PCR. Total RNA was extracted from HEK293
cells and U937 cells. cDNA was synthesized and then used for PCR
analysis using the following ALX-speciﬁc primer pair: (5′ to 3′) TTG
GTT TCC CTT TCA ACT GG as the sense primer and (5′ to 3′)
AGA CGT AAA GCA TGG GGT TG as the antisense primer.
Fluorescence-Associated Cell Sorting and Confocal Microscopy
Analyses. HEK293 cells were transfected with ×3HA-tagged FPRs;
24-h posttransfection cell surface expression of receptors was de-
termined using 1:100 dilution of anti-HA antibodies (Sigma-
Aldrich). A ﬁnal staining with anti-rabbit IgG was conducted.
Flow cytometry analysis was performed by analyzing 10,000
events using a FACS Calibur ﬂow cytometer (BD Biosciences)
equipped with CellQuest software (BD Biosciences), followed
by analysis using FlowJo (version 9.2, TreeStar). Results are
reported as median ﬂuorescence intensity units.
For receptor colocalization studies, cells were cotransfected
with HA-tagged FPR1 and FLAG-tagged ALX and replated onto
gelatin-coated 18-mm glass coverslips. Twenty-four hours later,
live cells were incubated with anti-FLAG M1 antibody and anti-
HA antibody (Sigma) directed against the N-terminal tags (1:1,000,
30 min). Cells were then ﬁxed with 4% formaldehyde in PBS for 15
min, washed three times in 50 mMTris base pH 7.4, 150 mMNaCl,
1 mM CaCl2, and blocked and permeabilized in blocking buffer
(0.1% Triton X-100, 3% milk, 1 mm CaCl2, and 50 mm Tris·HCl,
pH 7.4). Next, cells were stained with ﬂuorescently conjugated
secondary antibody (Alexa 488/594 1:500; Invitrogen). Coverslips
were mounted using vectastain (Vector Laboratories) containing
DAPI and visualized using a Zeiss LSM confocal microscope.
BRET Assay in Living Cells.HEK293 cells were transiently transfected
as described above. The donor:acceptor ratio was varied for op-
timization of BRET conditions and the optimum ratio of 1:1 was
used for subsequent transfections. Expression levels of the donor
and acceptor constructs were determined using ﬂuorescence mi-
croscopy and luminometry. Twenty-four hours posttransfection,
cells were washed and transferred into 96-well black optiplates
(Perkin-Elmer) using Hepes-buffered Ham’s F-12 media (Sigma-
Aldrich). For end-point assays, 24 h after transfection, cells were
stimulated with ligands for 10 min. Coelenterazine-h (Invitrogen)
was added in Hepes-buffered Ham’s F-12 to a ﬁnal concentration
of 5 μM and readings were collected immediately following this
addition using the Polarstar Omega plate reader (BMG Labtech)
that allows simultaneous dual-emission detection. For real-time
experiments coelenterazine-h was added to a ﬁnal concentration
of 5 μM directly before ligand injection. Readings were taken
immediately at 0.2-s intervals for 40 s followed by 3-s intervals
for 160 s and 60 s intervals for 700 s. Cells were kept at 37 °C
throughout the BRET measurements. The BRET ratio is deﬁned
as emission at 530 nm (light emitted by EYFP)/emission at 485
(light emitted by Rluc). The normalized BRET ratio was calcu-
lated by subtracting the BRET ratio obtained in cells expressing
the donor only (Rluc) from cells coexpressing both donor (Rluc)
and acceptor (EYFP)-tagged constructs, as described before (3).
Proteome Proﬁler Arrays. FPR1, ALX, or FPR1 +ALX-transfected
HEK293 cells were stimulated with agonist as per experimental
design. Typically, we used AnxA1 (10−8 M), SAA (10−7 M), or
peptide Ac2-26 (10−5 M) with an incubation time of 10 min, using
resting cells as control. Lysates were prepared and protein quan-
tiﬁcation carried out using the Bio-Rad protein assay (Bio-Rad
Laboratories) according to the manufacturer’s instruction. Each
sample was then used for the human phospho-MAPK array kit
(R&D Systems) used according to the manufacturer’s instructions.
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Brieﬂy, cell lysates (200 μg) were deposited on nitrocellulose
membranes, spotted in duplicate with capture and control anti-
bodies. A phospho site-speciﬁc biotinylated antibody mixture was
used to detect phosphorylated kinases. The arrays were exposed to
streptavidin-HRP and the ECL detection system before de-
velopment on X-ray ﬁlms. Spots were identiﬁed by alignment
with the grid provided in the kit.
Isolation of Human Primary Neutrophils and Monocytes. All volun-
teers gave informed consent to blood collection and cell sepa-
ration, as per the City and the East Ethics Committee (reference
05/Q0603/34, London). Peripheral blood from healthy donors
was collected by i.v. withdrawal in 3.2% (wt/vol) sodium citrate
solution (1:10). Polymorphonuclear leukocytes were isolated
from blood via density centrifugation on a Histopaque 1119/1077
gradient (Sigma-Aldrich) according to the manufacturer’s in-
structions and suspended in PBS + 0.5% BSA. Human primary
monocytes were separated using the RossetteSep cell isolation kit
(Stem Cell Technologies) according to manufacturer instructions.
Western Blotting and Coimmunoprecipitations.Western blotting was
carried out using transfected HEK293 cells, U937 monocytes,
human primary monocytes, or neutrophils. For dimerization
studies, HEK293 cells were transfected with FPR1 × 3Flag, ALX ×
3HA, and/or FPR1 × 3HA, ALX × 3HA or FPR3 × 3HA con-
structs and, 24 h later, stimulated for 10 min with the agonists.
Cells were scraped into lysis buffer containing PBS + 0.1% n-
dodecyl-β maltoside and a protease inhibitor mixture. For coim-
munoprecipitations (co-IPs), the lysates were incubated with
antihemagglutinin (HA) agarose beads and incubated at room
temperature for another 2 h. SDS loading buffer was added to
the samples and subjected to Western blotting using a 1:1,000
dilution of the anti-Flag antibody M2. Secondary antibody
IRDye 800CW goat anti-mouse IgG (LI-COR Biotechnology)
was used at a 1:10,000 dilution and imaged using the LI-COR
Odyssey Infrared Image system. The proteinmarker used was a Full-
Range Rainbow Molecular Weight Marker (GE Healthcare).
IL-10 Production from HumanMonocytes. Isolated human monocytes
(1 × 106) were incubated in 250 μL medium in round-bottomed
96-well plates at 37 °C, in a 5% CO2 atmosphere. In some cases,
AnxA1 was added at 10−8 M, before or after pretreatment for
10 min at 37 °C with the p38 inhibitor SB203580 (10−7 M; Sigma-
Aldrich). After a 6-h incubation, cell-free supernatants were har-
vested and used to quantify human IL-10 levels with a speciﬁc
ELISA (eBioscience), using the manufacturer’s instructions.
Assessment of Apoptosis.Freshly prepared neutrophils were treated
with SAA (10 μg/mL) in the presence or absence of the JNK
inhibitor SP600125 (20 μM; Calbiochem) after a 30-min pre-
incubation with Ac2-26 (0–10−5 M). Cells were then incubated
for an additional 6, 12, or 24 h at 37 °C in a 5% CO2 atmosphere.
Neutrophils were stained with FITC-AnxAV and propidium io-
dide (PI) using the apoptosis detection kit from BD Pharmingen,
following manufacturer instructions, and analyzed by ﬂow cy-
tometry (BD FACSCalibur).
Animal Experiments.Animals were used according to the guidelines
of the Queen Mary University of London Ethical Committee for
the Use of Animals. Animal work was performed according to
Home Ofﬁce Regulations (Guidance on the Operation of Ani-
mals, Scientiﬁc Procedures Act, 1986). Male C57BL/6 (Charles
River) and Alx-Fpr2/3 KO (4) mice (20–25 g body weight) were
used. Mice were maintained on a standard chow pellet diet with
tap water ad libitum. In the ﬁrst set of experiments, mice were
treated i.p. with human recombinant AnxA1 (1 μg) or saline.
Peritoneal cavities were washed 6 h later with 3 mL of PBS,
containing 3 mmol/L ethylenediamine tetraacetic acid. In a sec-
ond set of experiments, mice were injected with 10 mg/kg i.p. of
Escherichia coli LPS (serotype 0111:B4, speciﬁc activity, >500,000
units/mg) and peritoneal cavity was washed, and the contents were
collected from 6 to 24 h later. IL-10 was measured in peritoneal
lavages by the murine Ready-Set-Go ELISA kit according to the
manufacturer’s instructions (eBioscience). Mouse AnxA1 was
measured by an in-house ELISA.
Statistical Analysis. The data reported are the mean ± SEM of at
least three independent experiments, each performed at least
in duplicate. Statistical analysis was performed using one-way
ANOVA or, in the case of apoptosis in primary cells, two-way
ANOVA, taking a P value less than 0.05 as signiﬁcant.
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Fig. S1. Expression of ALX, FPR1, and FPR3 in transfected HEK293 cells. (A) ALX expression in HEK293 cells and U937 monocytes using reverse transcription
PCR, showing a single band corresponding to the ALX gene product. (B) FACS analysis to show expression of epitope-tagged (3HA) FPR1, ALX, and FPR3
constructs in nonpermeabilized HEK293 cells. (C) Confocal microscopy showing expression of epitope-tagged FPR1, ALX, and FPR3 constructs in non-
permeabilized HEK293 cells and ALX-EYFP–expressing cells. (D) FPR1 homodimerization and FPR1 heterodimerization with ALX and FPR3 as demonstrated by
coimmunoprecipitation (Co-IP): FPR1 × 3Flag construct was coexpressed in HEK293 cells either with FPR1 × 3HA, ALX × 3HA, or FPR3 × 3HA constructs. Some
cells were stimulated for 10 min with Ac2-26 (10−5 M) 24 h posttransfection. Co-IP of these samples with anti-HA agarose beads (H) and immunoblotting with
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Fig. S2. Lack of interaction between FPR1 and ALX and the angiotensin 1 receptor. (A) BRET: HEK293 cells were transfected with either FPR1-Rluc and Ang1-
EYFP or ALX-Rluc and Ang1-EYFP constructs. Twenty-four-posttransfection cells were stimulated with Ac2-26 (10−5 M) or Ang II (10−5 M). As positive control,
some cells were transfected with β-arrestin–Rluc and angiotensin receptor type 1 (Ang-EYFP) constructs and stimulated with Ang II (10−6 M) for 10 min. The
data show mean ± SEM of three independent experiments. ***P < 0.001. (B) Coimmunoprecipitation: Cells were transfected with FPR1 × 3Flag, ALX × 3Flag
along with angiotensin II type 1 receptor (AT1R) × 3HA constructs. Immunoprecipitations were performed using the anti-HA agarose beads and immuno-
blotted with the anti-Flag M2 antibody. (C) Co-IP, as in B, but using ALX × 3Flag along with Ang1R × 3HA constructs.
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Fig. S3. Validation of the LXA4 used in the BRET experiments. (A) High-pressure liquid chomatography (HPLC) trace for LXA4 standard. (B) HPLC trace, (C) UV
spectrum, and (D) MS-MS spectrum for commercially sourced LXA4 used in this study. The MS-MS spectrum with diagnostic ions, the UV-conjugated tetraene
chromatophore, and chromatographic behavior are three key points conﬁrming the correct structure of lipoxin A4 used in the present experiments.
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Fig. S4. Agonist-induced homodimerization of ALX using BRET. (A) HEK293 cells, transfected with ALX-Rluc and ALX-EYFP, were stimulated with AnxA1,
LXA4, and SAA at the indicated concentrations for 10 min. Some cells were also preincubated with either SAA or LXA4 at concentrations reported in the ﬁgure,
for 5 min before AnxA1 addition for an additional 10 min. *P < 0.05 vs. vehicle-treated cells (white bar). (B) Lack of homodimerization of ALX in the presence of
different concentrations of SAA. AnxA1 (10−8 M) used as positive control. Data are mean ± SEM of three experiments and have been calculated against re-
spective unstimulated ALX/ALX values. *P < 0.05 as indicated. In both sets of experiments, some cells were transfected with β-arrestin–Rluc and angiotensin II
type 1 receptor (AT1R-EYFP) constructs and stimulated with Ang II (10−6 M) for 10 min.









































Fig. S5. ALX receptor-mediated signaling in response to its anti-inﬂammatory agonists AnxA1 and compound 43 and proinﬂammatory agonist SAA.
(A) Phosphorylation status of Moesin. HEK293 cells were transfected with ALX receptor and stimulated with compound 43 (10−6 M), SAA (10−7 M), and AnxA1
(10−8 M) for 10 min. Lysates were subjected to Western blotting analysis using antibodies against the phosphorylated or unphosphorylated Moesin [phospho-
Moesin (pMoesin) or Moesin antibody, which also detects Radixin]. (B) Densitometry analysis of three independent Western blot experiments.
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Fig. S6. Identiﬁcation of ALX/ALX proresolving signaling signature. (A) Proteome proﬁler array on ALX-transfected HEK293 cells stimulated with AnxA1 (10−8
M) or SAA (10−7 M) for 10 min (see Materials and Methods for details). (B) Western blotting analyses to detect the phosphorylation status of p38, MAPKAPK,
and Hsp27 in ALX-HEK293 cells. Cells (1 × 106) were treated for 10 min with vehicle (Ctrl), AnxA1 (10−8 M), or SAA (10−7 M) and lysates subjected to Western
blotting and probed with antibodies against phosphorylated and unphosphorylated p38, MAPKAPK, and Hsp27.
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Fig. S7. Densitometric analysis of phosphorylation states of a number of serine/threonine kinases in ALX-transfected HEK293 cells as shown in Fig. S5. Results
are expressed in arbitrary units of densitometry.
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Fig. S8. Concentration–response proﬁles of phospho-Hsp27 in ALX-HEK293 cells stimulated for 10 min with the reported concentrations of (A) AnxA1, (B) LL-
37, or (C) SAA.
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Fig. S9. Densitometric analysis of phosphorylation states of serine/threonine kinases in FPR1, ALX, and FPR1 + ALX-transfected HEK293 cells treated with Ac2-
26 (10−5 M) for 10 min; see Fig. 4 for correspondent proﬁler. Results are expressed in arbitrary units of densitometry.
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